Determining whether ADC Therapeutics (ADCT) represents a favorable investment requires analyzing its clinical pipeline of antibody-drug conjugates targeting hematological and solid tumor cancers, its cash runway, and ongoing trial data readouts. While growth-oriented biotechnology investors are attracted to its targeted oncology therapies, clinical-stage biopharmaceutical equities carry high volatility and developmental risks that necessitate rigorous due diligence.